Sarepta Therapeutics, Inc. (0L35.L)
USD 98.49
(-1.78%)
USD 98.49
(-1.78%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -267.82 Million USD | 50.05% |
| 2022 | -536.2 Million USD | -19.23% |
| 2021 | -449.71 Million USD | 20.29% |
| 2020 | -564.16 Million USD | -8.01% |
| 2019 | -522.32 Million USD | -52.0% |
| 2018 | -343.62 Million USD | -100.21% |
| 2017 | -171.63 Million USD | 35.65% |
| 2016 | -266.73 Million USD | -21.14% |
| 2015 | -220.18 Million USD | -64.58% |
| 2014 | -133.78 Million USD | -48.19% |
| 2013 | -90.28 Million USD | -203.96% |
| 2012 | -29.7 Million USD | 17.32% |
| 2011 | -35.92 Million USD | -71.62% |
| 2010 | -20.93 Million USD | -35.0% |
| 2009 | -15.5 Million USD | 43.52% |
| 2008 | -27.45 Million USD | 17.07% |
| 2007 | -33.1 Million USD | -0.38% |
| 2006 | -32.98 Million USD | -88.3% |
| 2005 | -17.51 Million USD | 30.06% |
| 2004 | -25.04 Million USD | -32.69% |
| 2003 | -18.87 Million USD | 25.52% |
| 2002 | -25.34 Million USD | -64.52% |
| 2001 | -15.4 Million USD | -50.4% |
| 2000 | -10.24 Million USD | -23.39% |
| 1999 | -8.3 Million USD | -7.79% |
| 1998 | -7.7 Million USD | -97.44% |
| 1997 | -3.9 Million USD | -77.27% |
| 1996 | -2.2 Million USD | 15.38% |
| 1995 | -2.6 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 34.9 Million USD | 41.75% |
| 2024 Q2 | -701 Thousand USD | -102.01% |
| 2023 Q2 | -133.51 Million USD | 3.31% |
| 2023 Q4 | 24.62 Million USD | 218.15% |
| 2023 Q3 | -20.84 Million USD | 84.39% |
| 2023 FY | -267.82 Million USD | 50.05% |
| 2023 Q1 | -138.08 Million USD | -29.26% |
| 2022 Q3 | -131.35 Million USD | 37.79% |
| 2022 FY | -536.2 Million USD | -19.23% |
| 2022 Q4 | -106.83 Million USD | 18.67% |
| 2022 Q1 | -86.88 Million USD | 17.89% |
| 2022 Q2 | -211.13 Million USD | -143.01% |
| 2021 Q4 | -105.81 Million USD | -207.08% |
| 2021 Q1 | -151.86 Million USD | 11.04% |
| 2021 Q2 | -167.57 Million USD | -10.34% |
| 2021 FY | -449.71 Million USD | 20.29% |
| 2021 Q3 | -34.45 Million USD | 79.44% |
| 2020 Q3 | -137.06 Million USD | 0.93% |
| 2020 FY | -564.16 Million USD | -8.01% |
| 2020 Q1 | -118.02 Million USD | 48.73% |
| 2020 Q2 | -138.35 Million USD | -17.22% |
| 2020 Q4 | -170.71 Million USD | -24.55% |
| 2019 Q3 | -123.59 Million USD | 55.12% |
| 2019 Q1 | -76.38 Million USD | 45.19% |
| 2019 Q2 | -275.36 Million USD | -260.49% |
| 2019 Q4 | -230.21 Million USD | -86.28% |
| 2019 FY | -522.32 Million USD | -52.0% |
| 2018 Q1 | -30.73 Million USD | -32.8% |
| 2018 Q4 | -139.36 Million USD | -98.81% |
| 2018 Q3 | -70.09 Million USD | 32.22% |
| 2018 FY | -343.62 Million USD | -100.21% |
| 2018 Q2 | -103.42 Million USD | -236.47% |
| 2017 Q4 | -23.14 Million USD | 49.58% |
| 2017 FY | -171.63 Million USD | 35.65% |
| 2017 Q3 | -45.9 Million USD | 27.52% |
| 2017 Q2 | -63.33 Million USD | -61.39% |
| 2017 Q1 | -39.24 Million USD | 55.6% |
| 2016 Q4 | -88.39 Million USD | -56.36% |
| 2016 Q2 | -62.1 Million USD | -4.02% |
| 2016 FY | -266.73 Million USD | -21.14% |
| 2016 Q1 | -59.7 Million USD | 7.37% |
| 2016 Q3 | -56.53 Million USD | 8.96% |
| 2015 FY | -220.18 Million USD | -64.58% |
| 2015 Q4 | -64.45 Million USD | -24.51% |
| 2015 Q3 | -51.76 Million USD | -22.93% |
| 2015 Q2 | -42.1 Million USD | 31.93% |
| 2015 Q1 | -61.86 Million USD | -38.33% |
| 2014 FY | -133.78 Million USD | -48.19% |
| 2014 Q2 | -30.27 Million USD | -20.5% |
| 2014 Q3 | -33.67 Million USD | -11.25% |
| 2014 Q4 | -44.72 Million USD | -32.8% |
| 2014 Q1 | -25.12 Million USD | 23.53% |
| 2013 Q2 | -17.08 Million USD | -10.85% |
| 2013 Q3 | -24.93 Million USD | -45.92% |
| 2013 Q4 | -32.84 Million USD | -31.75% |
| 2013 Q1 | -15.41 Million USD | -48.69% |
| 2013 FY | -90.28 Million USD | -203.96% |
| 2012 FY | -29.7 Million USD | 17.32% |
| 2012 Q1 | -6.87 Million USD | 23.62% |
| 2012 Q2 | -5.55 Million USD | 19.16% |
| 2012 Q3 | -6.9 Million USD | -24.26% |
| 2012 Q4 | -10.36 Million USD | -50.14% |
| 2011 Q3 | -11.27 Million USD | -11.32% |
| 2011 Q1 | -5.53 Million USD | -217.87% |
| 2011 Q4 | -9 Million USD | 20.15% |
| 2011 Q2 | -10.12 Million USD | -83.06% |
| 2011 FY | -35.92 Million USD | -71.62% |
| 2010 Q1 | -7.73 Million USD | -95.62% |
| 2010 FY | -20.93 Million USD | -35.0% |
| 2010 Q2 | -7.66 Million USD | 0.88% |
| 2010 Q3 | -3.79 Million USD | 50.48% |
| 2010 Q4 | -1.74 Million USD | 54.17% |
| 2009 FY | -15.5 Million USD | 43.52% |
| 2009 Q3 | -2.92 Million USD | 42.27% |
| 2009 Q4 | -3.95 Million USD | -35.23% |
| 2009 Q2 | -5.06 Million USD | -42.08% |
| 2009 Q1 | -3.56 Million USD | -23.2% |
| 2008 FY | -27.45 Million USD | 17.07% |
| 2008 Q3 | -5.93 Million USD | -21.72% |
| 2008 Q2 | -4.87 Million USD | 64.51% |
| 2008 Q1 | -13.74 Million USD | -142.53% |
| 2008 Q4 | -2.89 Million USD | 51.27% |
| 2007 Q2 | -8.84 Million USD | 12.35% |
| 2007 FY | -33.1 Million USD | -0.38% |
| 2007 Q4 | -5.66 Million USD | 33.42% |
| 2007 Q3 | -8.51 Million USD | 3.69% |
| 2007 Q1 | -10.08 Million USD | -14.97% |
| 2006 FY | -32.98 Million USD | -88.3% |
| 2006 Q4 | -8.77 Million USD | -20.62% |
| 2006 Q3 | -7.27 Million USD | 1.97% |
| 2006 Q2 | -7.41 Million USD | 22.06% |
| 2006 Q1 | -9.51 Million USD | -94.06% |
| 2005 Q2 | -5.14 Million USD | 7.16% |
| 2005 Q1 | -5.54 Million USD | -12.32% |
| 2005 Q4 | -4.9 Million USD | -155.79% |
| 2005 Q3 | -1.91 Million USD | 62.75% |
| 2005 FY | -17.51 Million USD | 30.06% |
| 2004 FY | -25.04 Million USD | -32.69% |
| 2004 Q3 | -5.12 Million USD | 29.16% |
| 2004 Q4 | -4.93 Million USD | 3.63% |
| 2004 Q2 | -7.23 Million USD | 6.72% |
| 2004 Q1 | -7.75 Million USD | -8.3% |
| 2003 Q1 | -3.48 Million USD | 16.15% |
| 2003 Q4 | -7.15 Million USD | -52.98% |
| 2003 FY | -18.87 Million USD | 25.52% |
| 2003 Q2 | -3.55 Million USD | -2.08% |
| 2003 Q3 | -4.67 Million USD | -31.67% |
| 2002 Q4 | -4.15 Million USD | 22.7% |
| 2002 Q1 | -7.89 Million USD | -66.87% |
| 2002 Q2 | -7.92 Million USD | -0.33% |
| 2002 Q3 | -5.37 Million USD | 32.2% |
| 2002 FY | -25.34 Million USD | -64.52% |
| 2001 Q4 | -4.73 Million USD | -41.46% |
| 2001 FY | -15.4 Million USD | -50.4% |
| 2001 Q3 | -3.34 Million USD | 11.62% |
| 2001 Q2 | -3.78 Million USD | -6.9% |
| 2001 Q1 | -3.54 Million USD | -2.53% |
| 2000 Q3 | -2.59 Million USD | 12.34% |
| 2000 Q2 | -2.95 Million USD | -138.25% |
| 2000 FY | -10.24 Million USD | -23.39% |
| 2000 Q1 | -1.24 Million USD | 48.31% |
| 2000 Q4 | -3.45 Million USD | -33.28% |
| 1999 Q1 | -1.6 Million USD | 36.0% |
| 1999 FY | -8.3 Million USD | -7.79% |
| 1999 Q3 | -2.1 Million USD | -10.53% |
| 1999 Q4 | -2.4 Million USD | -14.29% |
| 1999 Q2 | -1.9 Million USD | -18.75% |
| 1998 Q2 | -1.7 Million USD | -13.33% |
| 1998 FY | -7.7 Million USD | -97.44% |
| 1998 Q4 | -2.5 Million USD | -38.89% |
| 1998 Q3 | -1.8 Million USD | -5.88% |
| 1998 Q1 | -1.5 Million USD | -50.0% |
| 1997 Q1 | -600 Thousand USD | 16.67% |
| 1997 Q2 | -1.2 Million USD | -100.0% |
| 1997 Q3 | -900 Thousand USD | 25.0% |
| 1997 FY | -3.9 Million USD | -77.27% |
| 1997 Q4 | -1 Million USD | -11.11% |
| 1996 Q3 | -590 Thousand USD | 0.0% |
| 1996 Q1 | -430 Thousand USD | 0.0% |
| 1996 Q2 | -590 Thousand USD | -37.21% |
| 1996 Q4 | -720 Thousand USD | -22.03% |
| 1996 FY | -2.2 Million USD | 15.38% |
| 1995 FY | -2.6 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 237.74% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -175.095% |
| Myriad Genetics, Inc. | -123.7 Million USD | -116.511% |
| Evolus, Inc. | -49.23 Million USD | -443.993% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 24.286% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 119.839% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 31.588% |
| uniQure N.V. | -282.87 Million USD | 5.319% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -380.35% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 2.964% |
| bluebird bio, Inc. | -244.26 Million USD | -9.646% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -455.651% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 5.086% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 349.645% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -264.416% |
| Dynavax Technologies Corporation | -37.02 Million USD | -623.301% |
| Editas Medicine, Inc. | -169.18 Million USD | -58.306% |
| FibroGen, Inc. | -281.81 Million USD | 4.965% |
| Geron Corporation | -193.94 Million USD | -38.093% |
| Blueprint Medicines Corporation | -486.27 Million USD | 44.924% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 113.547% |
| Illumina, Inc. | -1.06 Billion USD | 74.946% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 41.848% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -584.045% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 206.745% |
| Cara Therapeutics, Inc. | -121.49 Million USD | -120.44% |
| Adicet Bio, Inc. | -152.03 Million USD | -76.156% |
| Insmed Incorporated | -709.62 Million USD | 62.258% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 48.025% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 124.632% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -499.601% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -4983.014% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 98.097% |
| Waters Corporation | 817.67 Million USD | 132.754% |
| Zoetis Inc. | 3.06 Billion USD | 108.727% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 103.905% |
| Biogen Inc. | 1.29 Billion USD | 120.653% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 2.256% |
| Nektar Therapeutics | -137.42 Million USD | -94.887% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -165.627% |
| Perrigo Company plc | 151.9 Million USD | 276.316% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | -15.529% |
| Heron Therapeutics, Inc. | -110.61 Million USD | -142.123% |
| Verastem, Inc. | -92.08 Million USD | -190.847% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 106.218% |
| Imunon, Inc. | -21.03 Million USD | -1173.507% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -494.144% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | -72.164% |
| Homology Medicines, Inc. | -48.25 Million USD | -455.018% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 106.618% |
| OPKO Health, Inc. | -157.02 Million USD | -70.566% |
| Exelixis, Inc. | 170.88 Million USD | 256.728% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 179.338% |
| TG Therapeutics, Inc. | 20.63 Million USD | 1398.037% |
| Incyte Corporation | 620.52 Million USD | 143.161% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 63.13% |